[go: up one dir, main page]

PE20210318A1 - RECOMBINANT LIVE IMMUNOGENIC COMPOSITION INCLUDING NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE SPIKE PROTEIN RBD OF SARS-COV-2 - Google Patents

RECOMBINANT LIVE IMMUNOGENIC COMPOSITION INCLUDING NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE SPIKE PROTEIN RBD OF SARS-COV-2

Info

Publication number
PE20210318A1
PE20210318A1 PE2021000033A PE2021000033A PE20210318A1 PE 20210318 A1 PE20210318 A1 PE 20210318A1 PE 2021000033 A PE2021000033 A PE 2021000033A PE 2021000033 A PE2021000033 A PE 2021000033A PE 20210318 A1 PE20210318 A1 PE 20210318A1
Authority
PE
Peru
Prior art keywords
cov
sars
subunit
ndv
rbd
Prior art date
Application number
PE2021000033A
Other languages
Spanish (es)
Inventor
Diaz Manolo Clemente Fernandez
Mayo Katherine Ivette Calderon
Neyra Aldo Staniee Rojas
Original Assignee
Farm Veterinarios S A C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farm Veterinarios S A C filed Critical Farm Veterinarios S A C
Priority to PE2021000033A priority Critical patent/PE20210318A1/en
Publication of PE20210318A1 publication Critical patent/PE20210318A1/en
Priority to ARP210103681A priority patent/AR124522A1/en
Priority to PCT/IB2022/050031 priority patent/WO2022149058A1/en
Priority to BR112022016492A priority patent/BR112022016492A2/en
Priority to MX2022004220A priority patent/MX2022004220A/en
Priority to CONC2022/0010353A priority patent/CO2022010353A2/en
Priority to ECSENADI202264620A priority patent/ECSP22064620A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a la obtencion de dos vacunas vivas recombinantes o vectorizadas de NDV que expresan la subunidad S1 y RBD de la proteina S del SARS-CoV-2, que al ser aplicada por via intranasal en modelo de animal hamster genera la produccion de anticuerpos neutralizantes contra el SARS-CoV-2. La invencion muestra ademas que estas vacunas vivas son compatibles para su uso combinado entre si, para inducir la produccion de anticuerpos neutralizantes contra el SARS-CoV-2 sin interferencia cruzada sustancial, lo que indica una sinergia entre ambas vacunas, en donde los virus recombinantes de NDV (rNDV-LS1-HN-RBD/SARS-CoV-2 (SEQ ID No. 7) y rNDV-LS1-S1-F/SARS-CoV-2 (SEQ ID No. 13)), logran expresar la subunidad S1 y RBD de la proteina S del SARS-CoV-2 en mamiferosThe present invention refers to the obtaining of two live recombinant or vectorized NDV vaccines that express the S1 and RBD subunit of the S protein of SARS-CoV-2, which when applied intranasally in a hamster animal model generates the production of neutralizing antibodies against SARS-CoV-2. The invention further shows that these live vaccines are compatible for their combined use with each other, to induce the production of neutralizing antibodies against SARS-CoV-2 without substantial cross-interference, indicating a synergy between both vaccines, where the recombinant viruses of NDV (rNDV-LS1-HN-RBD / SARS-CoV-2 (SEQ ID No. 7) and rNDV-LS1-S1-F / SARS-CoV-2 (SEQ ID No. 13)), manage to express the subunit S1 and RBD of SARS-CoV-2 protein S in mammals

PE2021000033A 2021-01-08 2021-01-08 RECOMBINANT LIVE IMMUNOGENIC COMPOSITION INCLUDING NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE SPIKE PROTEIN RBD OF SARS-COV-2 PE20210318A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PE2021000033A PE20210318A1 (en) 2021-01-08 2021-01-08 RECOMBINANT LIVE IMMUNOGENIC COMPOSITION INCLUDING NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE SPIKE PROTEIN RBD OF SARS-COV-2
ARP210103681A AR124522A1 (en) 2021-01-08 2021-12-28 LIVING RECOMBINANT IMMUNOGENIC COMPOSITION COMPRISING THE NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND RBD OF THE SARS-CoV-2 SPIKE PROTEIN
PCT/IB2022/050031 WO2022149058A1 (en) 2021-01-08 2022-01-04 Recombinant live immunogenic composition comprising newcastle disease virus (ndv) expressing the s1 subunit and the rbd of the spike protein of sars-cov-2
BR112022016492A BR112022016492A2 (en) 2021-01-08 2022-01-04 RECOMBINANT LIVE IMMUNOGENIC COMPOSITION COMPRISING NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND RBD OF THE SARS-COV-2 SPIKE PROTEIN
MX2022004220A MX2022004220A (en) 2021-01-08 2022-01-04 Recombinant live immunogenic composition comprising newcastle disease virus (ndv) expressing the s1 subunit and the rbd of the spike protein of sars-cov-2.
CONC2022/0010353A CO2022010353A2 (en) 2021-01-08 2022-07-22 Recombinant live immunogenic composition comprising the newcastle disease virus (ndv) expressing the s1 subunit and the rbd of the sars-cov-2 spike protein
ECSENADI202264620A ECSP22064620A (en) 2021-01-08 2022-08-17 RECOMBINANT LIVE IMMUNOGENIC COMPOSITION COMPRISING THE NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE RBD OF THE SARS-CoV-2 SPIKE PROTEIN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PE2021000033A PE20210318A1 (en) 2021-01-08 2021-01-08 RECOMBINANT LIVE IMMUNOGENIC COMPOSITION INCLUDING NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE SPIKE PROTEIN RBD OF SARS-COV-2

Publications (1)

Publication Number Publication Date
PE20210318A1 true PE20210318A1 (en) 2021-02-16

Family

ID=74855966

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000033A PE20210318A1 (en) 2021-01-08 2021-01-08 RECOMBINANT LIVE IMMUNOGENIC COMPOSITION INCLUDING NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE SPIKE PROTEIN RBD OF SARS-COV-2

Country Status (7)

Country Link
AR (1) AR124522A1 (en)
BR (1) BR112022016492A2 (en)
CO (1) CO2022010353A2 (en)
EC (1) ECSP22064620A (en)
MX (1) MX2022004220A (en)
PE (1) PE20210318A1 (en)
WO (1) WO2022149058A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4404961A4 (en) * 2021-09-20 2025-08-06 Laboratorio Avi Mex S A De C V Recombinant vaccine against COVID-19 to generate a cellular response in individuals with pre-existing immunity

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024174012A1 (en) * 2023-02-24 2024-08-29 Instituto Butantan Immunogenic composition, use thereof and process of obtaining a combined immunogenic composition against covid-19 and seasonal influenza

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2911A (en) * 2005-12-02 2014-05-31 Sinai School Medicine Chimeric Viruses presenting non-native surface proteins and uses thereof
WO2021229270A1 (en) * 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Recombinant vaccine against covid-19 in a viral vector
CN112011521A (en) * 2020-06-15 2020-12-01 浙江迪福润丝生物科技有限公司 Novel recombinant newcastle disease virus vector coronavirus vaccine candidate strain as well as construction method and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4404961A4 (en) * 2021-09-20 2025-08-06 Laboratorio Avi Mex S A De C V Recombinant vaccine against COVID-19 to generate a cellular response in individuals with pre-existing immunity

Also Published As

Publication number Publication date
CO2022010353A2 (en) 2022-08-09
ECSP22064620A (en) 2022-09-30
MX2022004220A (en) 2022-08-08
BR112022016492A2 (en) 2023-10-31
AR124522A1 (en) 2023-04-05
WO2022149058A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
CO2020011914A2 (en) Self-Assembling Nanostructure Vaccines
AR065076A1 (en) VACCINE AGAINST PAPILOMAVIRUS
ECSP22064620A (en) RECOMBINANT LIVE IMMUNOGENIC COMPOSITION COMPRISING THE NEWCASTLE DISEASE VIRUS (NDV) EXPRESSING THE S1 SUBUNIT AND THE RBD OF THE SARS-CoV-2 SPIKE PROTEIN
BRPI1015917A2 (en) recombinant rsv antigens.
CO6460752A2 (en) IMMUNE RESPONSE REINFORCED IN AVIAN SPECIES
MX2023011163A (en) Coronavirus vaccine formulations.
AR060565A1 (en) VACCINE FOR THE AVIARY FLU AND METHODS OF USE
CY1120430T1 (en) RECOMMENDED CDV COMPOSITIONS AND USES OF THESE
MX2022003435A (en) Development of a novel live attenuated african swine fever vaccine based in the deletion of gene i177l.
CL2021003211A1 (en) A modified live strain of porcine reproductive and respiratory syndrome virus (prrs), a vaccine comprising it and its use to treat prrs type ii. (divisional application no. 2123-2018)
BR112023005043A2 (en) VACCINE AGAINST COVID-19 BASED ON PIV5
MX2019003116A (en) New swine influenza vaccine.
PE20230171A1 (en) VACCINES AGAINST CORONAVIRUS AND METHODS OF USE
MX2020003591A (en) Recombinant non-pathogenic marek's disease virus constructs encoding multiple heterologous antigens.
AR103427A1 (en) VACCINE AGAINST AFTOSE FEVER
MX2018015756A (en) CONSTRUCTIONS OF VIRUSES OF MAREK'S DISEASE RECOMBINANTS NON-PATHOGENIC CODIFIERS OF ANTIGENS OF VIRUS OF INFECTIOUS LARYNOTRAKITISIS AND OF VIRUS OF INFECTIOUS BURSAL DISEASE.
AR094725A1 (en) PARVOVIRUS 5A PORCINO, METHODS OF USE AND VACCINE
MX2017011322A (en) Marker system, in particular for baculovirus-expressed subunit antigens.
MX2021004907A (en) IBV 4/91 VACCINE WITH HETEROLOGOUS SPICULAR PROTEIN.
MX2023012530A (en) COMPOSITION AND METHODS OF ADJUVATED VACCINE.
PE20170429A1 (en) VACCINE IN RECOMBINANT VECTOR OF AVIAN ADENOVIRUS SEROTYPE 9
UY40331A (en) Coronavirus vaccine
CL2013002631A1 (en) Infectious pancreatic necrosis virus (ipnv) avirulent because it comprises mature vp2 protein.
AR066823A1 (en) INCREASE IN PLANTS PERFORMANCE BY MODULATION OF GARP TRANSMISSION ZMRR10-P FACTOR
AR105160A1 (en) METHODS OF MODULATION OF CYTOSOLIC DNA SURVEILLANCE MOLECULES